Gilead Sciences to acquire Immunomedics in $21B deal

Gilead Sciences is set to acquire Immunomedics in a $21 billion dollar deal, which is expected to close in the fourth quarter of 2020. Dr. Behzad Aghazadeh, Immunomedics Executive Chairman, joins Yahoo Finance’s The First Trade with Alexis Christoforous and Brian Sozzi to discuss. …read more

Source:: Yahoo Finance

Discover Tomorrow’s Winning Stocks!
Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.